Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) Stock, Slashes PT
On May 30, Evercore ISI downgraded Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc. (RCKT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Maverick Capital Lee Ainslie | 5,199,218 | $34,678,784 | +1% | 0.61% |
| 2. | Suvretta Capital Management Aaron Cowen | 3,502,000 | $23,358,340 | +37% | 0.87% |
| 3. | BioImpact Capital Mpm Capital | 1,618,265 | $10,793,828 | +59% | 1.86% |
| 4. | Citadel Investment Group Ken Griffin | 1,509,004 | $10,065,057 | -64% | 0% |
| 5. | Prosight Capital Lawrence Hawkins | 1,480,000 | $9,871,600 | +36% | 3.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.08 | 20,000 | $101,600.00 | 792,680 | 2025-04-10 | Filing | |
| $4.70 | 21,099 | $99,165.30 | 26,774 | 2025-04-09 | Filing | |
| $14.75 | 1,355,932 | $19,999,997.00 | 17,628,567 | 2022-10-06 | Filing | |
| $17.34 | 22,000 | $381,513.00 | 517,639 | 2022-02-07 | Filing | |
| $56.00 | 247,720 | $13,872,320.00 | 17,530,044 | 2020-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.88 | 1,477 | $4,256.71 | 128,173 | 2025-07-03 | Filing | |
| $6.45 | 357 | $2,301.22 | 64,027 | 2025-05-20 | Filing | |
| $6.45 | 801 | $5,163.25 | 235,255 | 2025-05-20 | Filing | |
| $6.45 | 767 | $4,944.08 | 441,927 | 2025-05-20 | Filing | |
| $6.45 | 2,253 | $14,522.84 | 786,806 | 2025-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 196,028 | $580,243 | 0.06% | |
| 2. | 13,540 | $33,173 | 0% | |
| 3. | 442 | $1,083 | 0% | |
| 4. | 230 | $564 | 0% | |
| 5. | 75 | $184 | 0% |
News See All
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease.
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback
Sami Corwin, an analyst at William Blair, maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on May 27 with no price target, despite the company's recent difficulties.
Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death
Rocket Pharmaceuticals, Inc.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
10 Best US Stocks Under $10 to Buy Right Now
On March 12, Stephanie Guild of Robinhood and Marci McGregor of Bank of America Merrill Lynch shared their perspectives on the current state of the market and strategies for navigating uncertainty.
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory
We came across a bullish thesis on Rocket Pharmaceuticals, Inc. (RCKT) on Twitter by sharkbiotech. In this article, we will summarize the bulls’ thesis on RCKT. Rocket Pharmaceuticals, Inc.
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
